Crown Bioscience to Host Pre-Show Symposium on Translational Oncology in Boston
October 28, 2015
(SANTA CLARA, CALIF., OCT. 28, 2015) — CROWN BIOSCIENCE, A GLOBAL LEADER IN UTILIZING PREDICTIVE MODELS TO IMPROVE CLINICAL OUTCOMES, WILL BE HOSTING A SYMPOSIUM AT THE BOSTON MUSEUM OF SCIENCE ON NOV. 4, 2015, THE DAY BEFORE THE START OF THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS IN BOSTON.
The symposium, “Translational Oncology and the Rise of Immunotherapy … a Global Challenge That Requires a Personal Touch,” will focus on some of the latest developments in translational research including improving clinical relevance, predictive biomarker development and genomic approaches to personalized medicine. In addition to several industry authorities and thought leaders from global biopharmaceutical companies, two of Crown Bioscience’s own experts, Dr. Henry Li and Dr. Qian Shi, will present.
“The objective of the symposium is to foster a greater understanding of translational technologies in both research and clinical communities,” said Jean-Pierre Wery, Ph.D., president of Crown Bioscience. “These technologies connect the preclinical and clinical aspects of drug development and provide decision support tools as companies advance therapeutic candidates. Our goal is to share the latest scientific discoveries to help researchers identify the best candidates for clinical development.”
The symposium is for oncology R&D and clinical teams from industry and medical research. The number of spaces is limited; interested persons may request to join by sending an email to firstname.lastname@example.org.
In addition to hosting the symposium, Crown Bioscience will be exhibiting at the AACR-NCI-EORTC conference Nov. 5-9 in Booth 500 at the Hynes Convention Center. Leaders from the company will present eight posters during the conference and will also be on hand to discuss projects with show attendees. Poster topics include molecular pathology, drug resistance, immune mechanisms and biomarker development for anti-cancer therapeutics.
For more information, visit Crown Bioscience at Booth 500 or visit www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visitwww.crownbio.com.